Abstract

AIDS: Charles Farthing, M.D., Director of the AIDS Healthcare Foundation, is interviewed regarding combination antiretroviral therapy and adherence issues. Dr. Farthing is affiliated with the Medical School at University of California at Los Angeles and has been associated with many clinical trials. Farthing believes that it is important to aggressively treat depression with antidepressants in HIV-positive patients. He offers suggestions for dealing with complex drug regimens and increasing the likelihood of adherence. Farthing believes that combination therapies with two protease inhibitors are more tolerable than treatments using just one. He describes strategies for dealing with drug resistance and failing regimens.